Unlocking the Future of Dialysis
About Advent Access
Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and improve quality of life for kidney failure patients. The company’s first product is the av-Guardian™ - an award-winning implant technology that aims to improve vascular access reliability, enable less-painful cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform guided hemodialysis consistently and safely across dialysis care environments.
Non randomised safety and performance evaluation of the av-Guardian Vascular Access System for hemodialysis patients
Multi-center Singapore study at Singapore General Hospital, National University Hospital, supported by National Kidney Foundation, Singapore
Non randomised safety and performance evaluation of the av-Guardian Vascular Access System for deep AVF & for use of self-cannulating patients.
Waikato Hospital, New Zealand